Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alloxanthine; Oxyprim; Oxypurinol

Latest Information Update: 21 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Cardiome Pharma
  • Class Anti-ischaemics; Antigouts; Pyrazoles; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gout; Heart failure; Stomatitis

Most Recent Events

  • 15 May 2018 Cardiome Pharma is now called Correvio Pharma
  • 28 Feb 2006 Oxypurinol is available for partnering worldwide for the treatment of conjestive heart failure and gout (www.cardiome.com)
  • 11 Apr 2005 Data from a media release have been added to the Heart Failure therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top